In this study we use a pair of ZFNs, custom-designed to target a genomically unique sequence in the ADPGK gene (Figure 1A), to generate human tumour cell lines with frameshift mutations at the target site and which completely lack ADPGK protein by immunoblotting. The gene discussed is ADPGK; the disease is neoplasm.